πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,413 results for β€œACE” Clear

  1. Placebo with a matching appearance to 100 mg niraparib capsules, filled with an excipient blend for clinical development., NIRAPARIB TOSILATE MONOHYDRATE

    TESARO Bio Netherlands B.V.

    Homologous recombination deficiency advanced ovarian cancer

    phase 3 small molecule active

    1 trial

  2. Placebo, Atoris, 40 mg, tabletki powlekane

    Bial Portela & Companhia S.A.

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  3. Placebo, CEMIPLIMAB

    Ningbo Cancer Hospital

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  4. Placebo, DRY EXTRACT FROM CHASTE TREE FRUITS (7-11:1), EXTRACTION SOLVENT: ETHANOL 70% (V/V)

    Topiloric/Uriadec

    Primary Dysmenorrhea

    phase 3 small molecule active

    1 trial

  5. Placebo, Ebglyss 250 mg solution for injection in pre-filled syringe

    Almirall, S.A.

    Nummular Dermatitis

    phase 3 small molecule active

    1 trial

  6. Placebo, Etavopivat A 200 mg

    NovoThirteen

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  7. Placebo, Minirin, 4 mikrogramy/ml, roztwΓ³r do wstrzykiwaΕ„

    Bial Portela & Companhia S.A.

    Rare and ultra-rare glomerulonephritis

    phase 3 small molecule active

    1 trial

  8. Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10144

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  9. Placebo, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Lacuna Pharma Pty Ltd

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  10. Placebo, Paltusotine 40 mg tablets, Paltusotine 40 mg tablets

    Lacuna Pharma Pty Ltd

    Carcinoid syndrome

    phase 3 small molecule active

    1 trial

  11. Placebo, Simvastatina NORMON 40 mg comprimidos recubiertos con pelΓ­cula EFG

    The George Institute

    Fibrosis liber, chronic liver disease, alcoholic liver disease

    phase 3 small molecule active

    1 trial

  12. Placebo, Velcade and dexamethasone

    Centocor B.V.

    Multiple Myeloma

    phase 3 small molecule terminated

    1 trial

  13. Placebo, XPF-010

    Xenon Pharmaceuticals

    Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

    phase 3 small molecule active

    1 trial

  14. Placebo, capsule, ZYTIGA 500 mg film-coated tablets, Prednison acis 5 mg, Tabletten, Fuzuloparib

    Lacuna Pharma Pty Ltd

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  15. Placebo, oral solution, Maralixibat chloride

    Lacuna Pharma Pty Ltd

    Cholestatic Pruritus

    phase 3 small molecule active

    1 trial

  16. Placebos

    Jian Li

    Advanced Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  17. Plozasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Familial Chylomicronemia Syndrome

    phase 3 small molecule completed

    1 trial

  18. Plozasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Familial Chylomicronemia

    phase 3 small molecule active

    1 trial

  19. Plozasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Severe Hypertriglyceridemia

    phase 3 small molecule active

    1 trial

  20. Plozasiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Severe Hypertriglyceridemia

    phase 3 small molecule active

    2 trials

  21. Plozasiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia

    phase 3 small molecule active

    2 trials

  22. Plozasiran Injection Placebo, ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  23. Plozasiran Injection Placebo, ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  24. Ponesimod

    Vanda Pharmaceuticals Netherlands B.V.

    Moderate-to-severe Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources